ArticleJournal of oncology2012
To treat or not to treat: the role of adjuvant radioiodine therapy in thyroid cancer patients.
Article in Journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Horner syndrome after ethanol ablation for radioactive iodine therapy refractory papillary thyroid carcinoma.JCEM case reports · 2026Article
- Effects of High-dose Radioactive Iodine Therapy on Hormonal Profiles and Sperm Quality in Thyroidectomy Patients.Molecular imaging and radionuclide therapy · 2026Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Prognostic Indicators and Comparative Treatment Outcomes in High-Risk Thyroid Cancer with Laryngotracheal Invasion.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- A Method for Calculating Small Sizes of Volumes in Postsurgical Thyroid SPECT/CT Imaging.Life (Basel, Switzerland) · 2025Article
- Racial-Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System.Annals of surgical oncology · 2024Article
- Article
- Ferroptosis and circular RNAs: new horizons in cancer therapy.EXCLI journal · 2024Review
- Nuclear Imaging Modalities in the Diagnosis and Management of Thyroid Cancer.Current molecular medicine · 2024Review
- Efficacy of anlotinib combined with radioiodine to treat scalp metastasis of papillary thyroid cancer: A case report and review of literature.World journal of clinical cases · 2023Article
- Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?Annals of surgical oncology · 2021Article
- Article
- Article
- I-131 uptake in fat necrosis of the breast.Radiology case reports · 2017Article
- The pros and cons of routine central compartment neck dissection for clinically nodal negative (cN0) papillary thyroid cancer.Gland surgery · 2013Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioactive iodine (RAI) is used in treatment of patients with differentiated papillary and follicular thyroid cancer. It is typically used after thyroidectomy, both as a means of imaging to detect residual thyroid tissue or metastatic disease, as well as a means of treatment by ablation if such tissue is found. In this paper, we discuss the indications for and the mechanisms of RAI in the treatment of patients with thyroid cancer. We discuss the attendant risks and benefits that come with its use, as well as techniques used to optimize its effectiveness as an imaging tool and a therapeutic modality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.